Beyond AFP: The Next Generation of…
Blog Beyond AFP: The Next Generation of Liver Cancer Blood Testing Hepatocellular…
Liver Cancer Fusion Predictor at a Glance
Live Data Feed
Our blood test detects molecular signals associated with hepatocellular carcinoma, including early-stage disease. No hospital visit required. Results typically available within 24 hours after the laboratory receives the sample.
Liver cancer can develop without noticeable symptoms, and many patients are diagnosed only after the disease has progressed. For people at increased risk, effective surveillance and earlier detection are especially important.
Source: Tsilimigras DI, et al. Ann Surg. Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria. DOI: 10.1097/SLA.0000000000004346.
of at-risk patients received biannual ultrasound surveillance in a recent meta-analysis.
Source: Meta-Analysis: Utilisation of Hepatocellular Carcinoma Surveillance. Aliment Pharmacol Ther. DOI: 10.1111/apt.70403. PMID: 41077883.
In a meta-analysis of 145,396 patients with HCC, 58.2% of surveillance-detected patients received potentially curative treatment, compared with 34.0% of patients diagnosed outside surveillance.
Source: Singal AG, et al. J Hepatol. 2022;77:128–139. DOI: 10.1016/j.jhep.2022.01.023.
People at increased risk for HCC may be advised to undergo regular surveillance. However, adherence to recommended surveillance remains incomplete, and ultrasound performance can be limited in some patients. These challenges highlight the need for additional effective and accessible approaches to early detection.
Among patients whose HCC was not detected through surveillance, 65.4% were already beyond Milan criteria at diagnosis. In contrast, 64.6% of surveillance-detected HCCs were still within Milan criteria. Earlier detection can preserve opportunities for potentially curative treatment.
Source: Jou JH, et al. Dig Dis Sci. 2010;55:3591–3596. DOI: 10.1007/s10620-010-1366-3.
Source: Singal AG, et al. Clin Gastroenterol Hepatol. U.S. multicenter VA cohort.
Source: American Cancer Society, Cancer Facts & Figures 2026.
UPMC Collaboration: Liver Cancer Fusion Predictor testing is available for eligible patients through participating UPMC providers and designated collection locations.
Conventional evaluation for liver cancer often relies on imaging and, in selected cases, biopsy. The MoleculeDx Fusion-detect™ test begins with a simple blood sample, providing a convenient molecular approach to HCC screening. At-home blood collection is available through contracted phlebotomy partners, helping make screening more accessible for people at increased risk.
Performance shown reflects MoleculeDx clinical validation data. Test performance should be interpreted in the context of the study population and reference standard.
Clinical validation performance of the Liver Cancer Fusion Predictor across key diagnostic metrics.
The MoleculeDx process is designed to make blood-based liver cancer testing straightforward—from online ordering and sample collection through laboratory analysis and secure delivery of your report.
Schedule your at-home blood draw in minutes at booking.moleculedx.com. Pick a time that works for you.
A certified phlebotomy professional from Portamedic or Travalab visits your home to collect the required blood sample. The collection typically takes less than 10 minutes.
Your blood sample is analyzed for cancer-associated fusion transcripts, and the molecular signals are evaluated using the proprietary Liver Cancer Fusion Predictor.
Your laboratory report is delivered securely online. Results that warrant further evaluation should be discussed with an appropriate healthcare provider.
Certified phlebotomist at your scheduled time
MoleculeDx makes blood collection convenient by bringing qualified phlebotomy services to your home. Through our contracted partners, Portamedic and Travalab, patients can schedule blood collection without traveling to a hospital or laboratory.
Choose an available date and arrival window through our secure online booking system.
Our contracted partners, Portamedic and Travalab, provide in-home blood collection by qualified phlebotomy professionals. The blood draw typically takes less than 10 minutes.
Your sample is packaged and transported to the MoleculeDx laboratory according to validated specimen-handling procedures designed to preserve sample integrity.
Your laboratory report is delivered securely online, typically within 24 hours after the laboratory receives an acceptable sample.
Fusion-detect™ is MoleculeDx’s proprietary molecular detection and machine-learning platform. It detects cancer-associated fusion transcripts in serum and integrates these molecular signals using a machine-learning model to assess the presence of hepatocellular carcinoma.
Fusion-detect™ was developed from MoleculeDx research on cancer-associated fusion transcripts and has evolved through successive analytical and machine-learning models. The current Liver Cancer Fusion Predictor integrates multiple serum fusion-transcript signals to classify samples for the presence of hepatocellular carcinoma.
Liver cancer is a major cause of cancer-related death worldwide. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and outcomes are strongly influenced by the stage at which the cancer is detected.
MoleculeDx works with established mobile phlebotomy providers to make blood collection convenient for patients across our service area.
Provides mobile phlebotomy services, allowing patients to have blood collected conveniently at home.
Provides mobile phlebotomy services for convenient in-home blood collection and specimen handling.
Take a proactive step toward liver cancer detection. Order your test online and schedule convenient in-home blood collection.
Blog Beyond AFP: The Next Generation of Liver Cancer Blood Testing Hepatocellular…
Blog At-Home Blood Draw for Cancer Screening: A Simple Guide to Convenient…
Blog What Is HCC Liver Cancer? Screening Guidelines & Early Detection What…
MoleculeDx is a molecular diagnostics company developing blood-based tests for cancer detection. Our current focus is hepatocellular carcinoma (HCC), using cancer-associated fusion-transcript signals in serum and proprietary predictive models. Our goal is to extend this molecular diagnostic approach to additional cancers over time.
MoleculeDx develops blood-based cancer tests using cancer-associated fusion transcripts as molecular biomarkers. Our proprietary Fusion-detect™ technology combines multiple molecular signals with predictive models to improve cancer detection. For our current liver cancer test, this approach is designed to detect hepatocellular carcinoma from a blood sample while providing convenient access to sample collection.
MoleculeDx serves patients and healthcare providers seeking accessible blood-based cancer testing. Our current Liver Cancer Fusion Predictor is intended for individuals who may benefit from evaluation for hepatocellular carcinoma (HCC), including people with risk factors for liver cancer. Healthcare providers may also use MoleculeDx testing as part of patient evaluation and follow-up.
A separate prescription from your personal physician is not required to begin the ordering process. Patients may order the Liver Cancer Fusion Predictor online. When required, an authorized healthcare provider facilitates the laboratory order as part of the testing process. You may also discuss testing with your own healthcare provider.
Order the Liver Cancer Fusion Predictor through the MoleculeDx online ordering system. After completing the required information, you can arrange convenient in-home blood collection by a qualified phlebotomy professional. Your sample is then transported to the MoleculeDx laboratory for analysis.
Results are typically available within 24 hours after the MoleculeDx laboratory receives an acceptable blood sample. Turnaround time may vary if a sample requires additional review or does not meet laboratory acceptance criteria.
You will be notified electronically when your results are available. Your laboratory report can be accessed securely through the patient portal. Results that warrant further evaluation should be discussed with an appropriate healthcare provider.
Yes. MoleculeDx protects patient health information in accordance with applicable privacy and security requirements. Access to personal and medical information is limited to authorized individuals and service providers as necessary to support testing, reporting, and related services.
MoleculeDx testing is currently available in the United States. In-home blood collection is available through our contracted mobile phlebotomy providers, subject to service availability at the patient’s location. Samples are analyzed at the MoleculeDx laboratory.
© 2026 MoleculeDx Inc. All rights reserved.
Test results should be interpreted in the context of other clinical information and are not a substitute for evaluation by a qualified healthcare provider.